Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

baxter a/s - bleomycinsulfat - pulver til injektions-/infusionsvæske, opløsning - 15.000 ie

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

orifarm a/s - bleomycinsulfat - pulver til injektions-/infusionsvæske, opløsning - 15.000 ie

Den Europæiske Union - dansk - EMA (European Medicines Agency)

pfizer europe ma eeig - tofacitinib - arthritis, reumatoid - immunosuppressiva - rheumatoid arthritistofacitinib in combination with methotrexate (mtx) is indicated for the treatment of moderate to severe active rheumatoid arthritis (ra) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying antirheumatic drugs (dmards) (see section 5. tofacitinib can be given as monotherapy in case of intolerance to mtx or when treatment with mtx is inappropriate (see sections 4. 4 og 4. psoriatic arthritistofacitinib in combination with mtx is indicated for the treatment of active psoriatic arthritis (psa) in adult patients who have had an inadequate response or who have been intolerant to a prior disease modifying antirheumatic drug (dmard) therapy (see section 5. ulcerative colitistofacitinib is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent (see section 5. tofacitinib is indicated for the treatment of active polyarticular juvenile idiopathic arthritis (rheumatoid factor positive [rf+] or negative [rf-] polyarthritis and extended oligoarthritis), and juvenile psoriatic arthritis (psa) in patients 2 years of age and older, who have responded inadequately to previous therapy with disease modifying antirheumatic drugs (dmards). tofacitinib can be given in combination with methotrexate (mtx) or as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. ankylosing spondylitistofacitinib is indicated for the treatment of adult patients with active ankylosing spondylitis (as) who have responded inadequately to conventional therapy.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

roche registration ltd. - daclizumab - graft rejection; kidney transplantation - immunosuppressiva - zenapax er indiceret til forebyggelse af akut organafstødning i de novo allogen nyre transplantation og skal anvendes samtidig med en immunosuppressive regime, herunder cyclosporin og kortikosteroider i patienter, der ikke er meget vaccineret.

Danmark - dansk - SEGES Landbrug & Fødevarer

agroplanta gmbh & co. kg - additiv - flydende middel - 1000 g/l additiv

Den Europæiske Union - dansk - EMA (European Medicines Agency)

laboratorios lesvi s.l. - dimethylfumarat - multipel sklerose, recidiverende-remitterende - immunosuppressiva - dimethyl fumarate neuraxpharma is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

aristo pharma gmbh - quetiapin fumarat - filmovertrukne tabletter - 100 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

aristo pharma gmbh - quetiapin fumarat - filmovertrukne tabletter - 200 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

aristo pharma gmbh - quetiapin fumarat - filmovertrukne tabletter - 25 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

aristo pharma gmbh - quetiapin fumarat - filmovertrukne tabletter - 300 mg